News brief­ing: Pfiz­er kick­starts PhI­II tri­al for DMD gene ther­a­py, out­rac­ing Sarep­ta; Teva's re­for­mu­lat­ed schiz­o­phre­nia shot touts win in late-stage study

In the race to bring the first gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy in­to a Phase III tri­al, Pfiz­er has come out on top over com­peti­tor Sarep­ta, dos­ing its first pa­tient in the CIFFREO study, the phar­ma gi­ant said Thurs­day.

CIFFREO is ex­pect­ed to en­roll 99 male pa­tients, ages 4 through 7, across 55 clin­i­cal tri­al sites in 15 coun­tries, Pfiz­er said. The first of those pa­tients were ad­min­is­tered Pfiz­er’s ther­a­py, dubbed PF-06939926, on Dec. 29 at a Barcelona site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.